Kevin J. Hamblett - Concepedia

Concepedia

Author

Kevin J. Hamblett

Seagen (United States)

Also Known As

K J Hamblett, K. Hamblett, K. J. Hamblett, Kevin Hamblett, Kevin J Hamblett, Kevin J. Hamblett

45

Publications

2.3K

Citations

12

H-Index

35

Concepts

All Affiliations

Seagen (United States)Amgen (United States)Zymeworks (Canada)University of Washington Fred Hutch Cancer Center

KJ

About

Kevin J. Hamblett is an author at Seagen (United States) specializing in medicine, tumor biology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	535
2	Biomolecular Engineering	3	3	334
3	Engineering	2	2	98
4	Natural Sciences	1	1	128
5	Biochemistry	1	1	57

Kevin J. Hamblett

×

13

Publications

2.3K

Citations

12

H-Index

	Year	Citations
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate Kevin J. Hamblett, Peter D. Senter, Dana F. Chace, Clinical Cancer Research	2004	1.2K
Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides Michael Sun, Kevin S. Beam, Charles G. Cerveny, Bioconjugate Chemistry	2005	359
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment Charlotte F. McDonagh, Eileen Turcott, Lori Westendorf, Protein Engineering Design and Selection Medicinal ChemistryParental Antibody-drug ConjugatesMedicineDrug DiscoveryDrug Attachment	2006	236
SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm Kevin J. Hamblett, Allison P. Jacob, Jesse L. Gurgel, Cancer Research Protein SecretionDrug TargetingNatural SciencesLysosomal TransporterImmunology	2015	128
AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma Kevin J. Hamblett, Carl J. Kozlosky, Sophia Siu, Molecular Cancer Therapeutics	2015	99
Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics Charles G. Cerveny, C-L Law, R S McCormick, Leukemia Disease CellsImmunologyImmunologic MechanismImmune Checkpoint InhibitorAutoimmunity	2005	62
A Streptavidin−Biotin Binding System That Minimizes Blocking by Endogenous Biotin Kevin J. Hamblett, Brian B. Kegley, Don K. Hamlin, Bioconjugate Chemistry EngineeringGlycobiologyTumor BiologyOncologyTheranostics	2002	57
Altering Antibody–Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability Kevin J. Hamblett, Tiep Le, Brooke M. Rock, Molecular Pharmaceutics	2016	41
Abstract 3914: ZW49, a HER2-targeted biparatopic antibody-drug conjugate for the treatment of HER2-expressing cancers Kevin J. Hamblett, Phil W. Hammond, Stuart D. Barnscher, Cancer Research EngineeringImmunologyTumor BiologyHer2-expressing CancersOncology	2018	41
Role of Biotin-Binding Affinity in Streptavidin-Based Pretargeted Radioimmunotherapy of Lymphoma Kevin J. Hamblett, Oliver W. Press, Damon L. Meyer, Bioconjugate Chemistry	2004	30

Page 1